AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00792220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSU
Description: In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland.
Study NCT00792220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCCM
Description: In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
Study NCT01982656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
Study NCT01982656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
Study NCT03074838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial aortic valve implantation - TAVI
Description: After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
Study NCT03074838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical aortic valve replacement - SAVR
Description: The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
Study NCT00693771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Once daily and up-titrate accordingly
Study NCT00654550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon™ or Nexagon™ vehicle
Description: Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
Study NCT04163211 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal drain
Description: A latex-free drain (size 20F)
Study NCT00636298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, cetuximab
Description: Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks
Study NCT00355966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
Study NCT00355966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2 gel
Description: In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
Study NCT00397865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational booklet
Description: Parental perception of educational booklet and evaluating any change in child's weight.
Study NCT00569959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fasting 12+ hours
Description: fasting 12+ hours
Study NCT00569959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-fasting
Description: Non-fasting
Study NCT02510508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CRAFT
Description: CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
Study NCT02510508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed CRAFT Delivery
Description: CRAFT self-help book (Self Directed CRAFT Delivery)
Study NCT02510508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-intervention
Description: Non-intervention
Study NCT02510508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-intervention
Description: Non-intervention
Study NCT02219425 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endometrial biopsy
Study NCT02694289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Treatment/continuation of metformin therapy during admission
Study NCT02694289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous (sliding scale) Insulin
Description: Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
Study NCT02135926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
Study NCT02135926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical care
Description: Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
Study NCT00828204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-use autoinjector with a prefilled liquid Avonex syringe
Study NCT00828204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avonex prefilled syringe via manual IM injection
Study NCT00828204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9418 (interferon beta-1a)
Study NCT02863120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivacaine
Study NCT02863120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine HCl
Study NCT02863120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02863120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT04239014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
Study NCT04239014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
Study NCT04239014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match olaparib
Description: Per olaparib
Study NCT02373683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm-Heliox
Description: Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
Study NCT04960657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
Study NCT04960657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP38
Description: PACAP38 infusion
Study NCT01568242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phacoemlsification
Description: Transurgical measurement of temperature
Study NCT02753452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential Immersive Life Skills programming
Study NCT02753452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-residential life skills programming
Study NCT00590265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Northern Light Technology (SADelite lamp) bright light-therapy
Description: 10 000 lux for 30 minutes
Study NCT00590265 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Northern Light Technology (SADelite lamp) Dim light-therapy
Description: \<100 lux for 30 minutes
Study NCT01642589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
Description: 0.5 mL, Intramuscular
Study NCT01642589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, Intramuscular
Study NCT02758184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM-based coagulation monitoring
Study NCT02758184 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spine surgery
Study NCT02758184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine surgery
Study NCT00619710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Intravenous
Study NCT00619710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem-cilastatin
Description: Intravenous
Study NCT03752567 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: like group descriptions
Study NCT00670748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY ESO-1 T-cell receptor PBL
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study NCT00670748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
Study NCT00670748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study NCT00670748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT00670748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC NY ESO-1 vaccine
Description: Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
Study NCT02606513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Urography; CT Urography
Study NCT02390193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study.
Study NCT03172988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg is administered before anesthesia induction.
Study NCT03172988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.
Study NCT03172988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.
Study NCT03172988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study NCT03172988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study NCT03172988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study NCT04545580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
Study NCT04545580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be taken twice daily orally as tablet(s)
Study NCT04440904 — intervention group
Intervention type: DEVICE
Intervention: CT workstation (Syngo Via VB10B, Siemens, Germany)
Description: Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
Study NCT02668978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch™ Sealing Hemostat
Description: Hemopatch™ application over lung resection areas
Study NCT02668978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical technique
Description: Lung resuturing or restapling
Study NCT03422094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
Study NCT03422094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study NCT03422094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
Study NCT03422094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
Study NCT03422094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis for research
Description: -Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
Study NCT01815697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation
Description: Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Study NCT01287741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Study NCT04421027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Given orally
Study NCT04421027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT03071419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Parenting Intervention
Description: The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
Study NCT03071419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Parenting Intervention
Description: The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
Study NCT02581241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tilt table
Description: Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital